BR0317740A - Derivados de prostaglandinas para o tratamento de desconforto abdominal - Google Patents

Derivados de prostaglandinas para o tratamento de desconforto abdominal

Info

Publication number
BR0317740A
BR0317740A BR0317740-8A BR0317740A BR0317740A BR 0317740 A BR0317740 A BR 0317740A BR 0317740 A BR0317740 A BR 0317740A BR 0317740 A BR0317740 A BR 0317740A
Authority
BR
Brazil
Prior art keywords
treatment
abdominal discomfort
prostaglandin derivatives
abdominal
chloride channel
Prior art date
Application number
BR0317740-8A
Other languages
English (en)
Other versions
BRPI0317740B8 (pt
BRPI0317740B1 (pt
Inventor
Ryuji Ueno
Sachiko Kuno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32717850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0317740(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BR0317740A publication Critical patent/BR0317740A/pt
Publication of BRPI0317740B1 publication Critical patent/BRPI0317740B1/pt
Publication of BRPI0317740B8 publication Critical patent/BRPI0317740B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DERIVADOS DE PROSTAGLANDINAS PARA O TRATAMENTO DE DESCONFORTO ABDOMINAL". A presente invenção refere-se a um novo uso de um abridor de canal de cloreto, especialmente um composto de prostaglandina para o tratamento de desconforto abdominal. Ulteriormente descrito é um novo uso de um abridor de canal de cloreto, especialmente um composto de prostaglandina para o tratamento de distúrbios gastrointestinais funcionais.
BRPI0317740A 2002-12-27 2003-12-26 uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1 BRPI0317740B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43646302P 2002-12-27 2002-12-27
US43646202P 2002-12-27 2002-12-27
PCT/JP2003/016857 WO2004060377A1 (en) 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort

Publications (3)

Publication Number Publication Date
BR0317740A true BR0317740A (pt) 2005-11-22
BRPI0317740B1 BRPI0317740B1 (pt) 2018-09-18
BRPI0317740B8 BRPI0317740B8 (pt) 2021-05-25

Family

ID=32717850

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0317740A BRPI0317740B8 (pt) 2002-12-27 2003-12-26 uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1

Country Status (15)

Country Link
US (3) US7795312B2 (pt)
EP (2) EP2281564A3 (pt)
JP (2) JP4889219B2 (pt)
KR (2) KR101164838B1 (pt)
CN (1) CN1753680B (pt)
AR (1) AR042670A1 (pt)
AU (1) AU2003292556B2 (pt)
BR (1) BRPI0317740B8 (pt)
CA (1) CA2510051C (pt)
ES (1) ES2591252T3 (pt)
MX (1) MXPA05006981A (pt)
NO (1) NO335441B1 (pt)
NZ (1) NZ541110A (pt)
TW (1) TWI336254B (pt)
WO (1) WO2004060377A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
CA2502439C (en) * 2002-10-23 2011-11-22 Sucampo Ag Prostaglandin compounds for the treatment of obesity
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US8962688B2 (en) * 2005-04-12 2015-02-24 Sucampo Ag Method for the treatment of gastrointestinal disorders
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
CN104958298A (zh) * 2009-09-18 2015-10-07 阿得罗公司 阿片样受体拮抗剂用于胃肠道疾病的用途
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2841065A4 (en) * 2012-04-23 2015-09-16 Sucampo Ag METHOD FOR TREATING IRRITATION SYNDROME WITH RUNNING
CA2888021A1 (en) 2012-10-15 2014-04-24 Epizyme, Inc. Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
CA2041417C (en) 1990-05-01 2002-05-21 Ryuji Ueno Treatment of pancreatic disease with 15-keto-prostaglandin compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
DE69714698T2 (de) 1996-06-10 2002-12-05 Sucampo Ag Endothelin-antagonisten
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
US6197821B1 (en) * 1997-11-28 2001-03-06 R-Tech Ueno, Ltd. Endothelin antagonist
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
ATE267189T1 (de) 1999-10-15 2004-06-15 Sucampo Ag Bizyclische verbindungen zusammenstellung und verfahren zu ihrer stabilisierung
KR100874626B1 (ko) * 2000-04-06 2008-12-17 수캄포 아게 담즙 분비 촉진 조성물
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
WO2002094274A1 (en) 2001-05-18 2002-11-28 Sucampo Ag Cathartic composition
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel

Also Published As

Publication number Publication date
MXPA05006981A (es) 2005-12-14
US20040138308A1 (en) 2004-07-15
US20130217770A1 (en) 2013-08-22
TWI336254B (en) 2011-01-21
KR20120045051A (ko) 2012-05-08
JP2012031202A (ja) 2012-02-16
NZ541110A (en) 2008-11-28
CN1753680A (zh) 2006-03-29
EP1575596B1 (en) 2016-06-22
NO335441B1 (no) 2014-12-15
KR20050086950A (ko) 2005-08-30
ES2591252T3 (es) 2016-11-25
EP2281564A2 (en) 2011-02-09
WO2004060377A1 (en) 2004-07-22
BRPI0317740B8 (pt) 2021-05-25
AU2003292556A1 (en) 2004-07-29
US7795312B2 (en) 2010-09-14
NO20053623D0 (no) 2005-07-26
JP4889219B2 (ja) 2012-03-07
AR042670A1 (es) 2005-06-29
TW200418491A (en) 2004-10-01
CN1753680B (zh) 2010-12-08
BRPI0317740B1 (pt) 2018-09-18
JP2006513232A (ja) 2006-04-20
CA2510051A1 (en) 2004-07-22
NO20053623L (no) 2005-09-26
EP2281564A3 (en) 2012-09-05
KR101164838B1 (ko) 2012-07-11
EP1575596A1 (en) 2005-09-21
US20100298424A1 (en) 2010-11-25
CA2510051C (en) 2016-07-05
AU2003292556B2 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
BR0317740A (pt) Derivados de prostaglandinas para o tratamento de desconforto abdominal
BR0311494A (pt) Novos indóis substituìdos
HK1094421A1 (en) (S)-2-n-propylamino-5-hydroxytetralin as a d3-agonist
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
NO20032208D0 (no) Benzodiazepinderivater som GABA A reseptormodulatorer
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
MXPA03010232A (es) Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
TW200716520A (en) 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CY1108031T1 (el) Υποκατασταθεντα παραγωγα της καρβοστυριλης ως συναγωνιστες υποδοχεων υποτυπου 5-ht 1a
UA88773C2 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
BR0213094A (pt) Derivados de cromano como ligandos de 5-hidroxi-triptamina-6
BR0211972A (pt) Composição oftálmica
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MA27921A1 (fr) Systemes emulsifiants contenant des derives d'azetidine
ATE272617T1 (de) Sulfonamid-derivate
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
SE0101082D0 (sv) Novel use
DE602004009211D1 (de) Indazol-3-one und analoga und derivate davon, die die funktion des vanilloid-1-rezeptors (vr1) modulieren
BR0110871A (pt) Derivados de sulfonamida
SE0200198D0 (sv) New use
CR7039A (es) Modificacion cristalina de un depsipeptido ciclico con actividad mejorada
BR0110874A (pt) Derivados de sulfonamida
ATE418973T1 (de) Spirocyclopropyl-amide und -säuren und ihre therapeutischen anwendungen
AR106393A2 (es) Uso del abridor del canal de cloruro para preparar un compuesto farmacéutico para tratar el malestar abdominal

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF